PD-L1 crosslinking as a new strategy of 4-1BB agonism immunotherapy. Scientific Publication

Abstract

4-1BB has been considered a promising target in cancer immunotherapy for decades. Nevertheless, early 4-1BB-targeted agent demonstrated significant liver immuno-toxicity.

A new wave of 4-1BB-based therapy is being developed to circumvent hepatotoxicity with bispecific molecule that directs 4-1BB agonism to the tumor microenvironment by targeting tumor-associated immune checkpoint molecule, PD-L1.

CITATION Clin Cancer Res. 2022 Jun 1;clincanres.0541.2022-4-27 13:45:31.573. doi: 10.1158/1078-0432.CCR-22-0541